Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PTCT
SellHot AirPTC Therapeutics, Inc. · Healthcare · United States · $5.8B · Avg Vol: $67M/d
COMPANY DESCRIPTION
PTC Therapeutics, Inc. is a U.S. biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with rare diseases. The company specializes in RNA-focused science and has a portfolio of approved drugs and a robust pipeline targeting genetic disorders such as Duchenne muscular dystrophy and AADC deficiency. Its pioneering work in rare disease treatment and global commercial infrastructure provide a strong position in a high-need therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 698.8M | 937.8M | 806.8M | 1.7B | 35.3% | 1.0B | 1.3B | 1.4B | -11.0% |
| EPS | -7.79 | -8.37 | -4.73 | 8.58 | — | -0.67 | — | — | — |
| Shares | 73.1M | 75.7M | 77.7M | 81.5M | +11.4% | 83.5M | — | — | — |
| Debt | 1.5B | 2.2B | 2.5B | 2.7B | 22.8% | 3.0B | — | — | — |
| Equity | -347.1M | -818.6M | -1.1B | -205.3M | — | — | — | — | — |
| Op CF | -356.7M | -158.4M | -107.7M | 711.2M | — | -30.5M | — | — | — |
| Inv CF | 290.2M | -176.7M | 44.2M | -862.0M | — | — | — | — | — |
| Fin CF | 168.0M | 646.4M | 255.9M | 331.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc.(you) | $5.8B | 32 | Sell |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | 30 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
| EWTX | Edgewise Therapeutics, Inc. | $4.6B | 28 | Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
| LEGN | Legend Biotech Corporation | $3.9B | 30 | Sell |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 28 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| BLTE | Belite Bio, Inc | $6.1B | 42 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%